Strategic report Governance & remuneration Financial statements Investor information Shareholder information Share buy-back programme Share capital and control The Board has been authorised to issue and allot Ordinary Shares Details of our issued share capital and the number of shares held under Article 9 of the companys Articles of Association.
The in Treasury as at 31 December 2014 can be found in Note 33 to power under Article 9 and the authority for the company to make the financial statements, Share capital and share premium purchases of its own shares are subject to shareholder authorities account.
which are sought on an annual basis at our Annual General Meeting AGM.
Any shares purchased by the company may be Our Ordinary Shares are listed on the London Stock Exchange cancelled or held as Treasury shares or used for satisfying Share and are also quoted on the New York Stock Exchange NYSE in Options and Grants under Group Employee Share Plans.
the form of American Depositary Shares ADS.
Each ADS represents two Ordinary Shares.
For details of listed debt and We continued our long-term buy-back programme in 2014 and where it is listed refer to Note 32 to the financial statements, Net 14.7 million shares were purchased at a total cost of 238 million.
The date of the final share purchase in 2014 was 24 June 2014.
No shares were purchased in the period 25 June 2014 to Holders of Ordinary Shares and ADS are entitled to receive 19 February 2015. dividends when declared, the companys Annual Report or Annual Summary, to attend and speak at general meetings of the Our programme covers purchases of shares for cancellation or company, to appoint proxies and to exercise voting rights.
to be held as Treasury shares, in accordance with the authority renewed by shareholders at the AGM in May 2014, when the There are no restrictions on the transfer, or limitations on the company was authorised to purchase a maximum of just under holding, of Ordinary Shares and ADS and no requirements to 486 million shares.
Details of shares purchased, those cancelled, obtain approval prior to any transfers.
No Ordinary Shares or ADS and those held as Treasury shares are disclosed in Note 33 to the carry any special rights with regard to control of the company and financial statements, Share capital and share premium account.
there are no restrictions on voting rights.
Major shareholders have the same voting rights per share as all other shareholders.
There In determining specic share repurchase levels, the company are no known arrangements under which financial rights are held considers the development of free cash ow during the year.
Given by a person other than the holder of the shares and no known the impact of the sustained strength of Sterling on free cash ow, agreements on restrictions on share transfers or on voting rights.
the company suspended its share repurchase programme during Shares acquired through our share schemes and plans rank 2014.
Following the completion of the Novartis transaction, GSK equally with the other shares in issue and have no special rights.
intends to return to shareholders 4 billion of the net proceeds.
The trustees of our Employee Share Ownership Plan trusts have The company does not expect to make any Ordinary Share waived their rights to dividends on shares held by those trusts.
Exchange controls and other limitations Market capitalisation affecting security holders The market capitalisation, based on shares in issue excluding Other than certain economic sanctions, which may be in force from Treasury shares, of GSK at 31 December 2014 was 66.92 time to time, there are currently no applicable laws, decrees or billion.
regulations restricting the import or export of capital or affecting the At that date, GSK was the fourth largest company by market remittance of dividends or other payments to holders of the capitalisation in the FTSE index.
companys shares who are non-residents of the UK.
Similarly, other than certain economic sanctions which may be in force from time to Share price time, there are no limitations relating only to non-residents of the UK 2014 2013 2012 under English law or the companys Articles of Association on the right to be a holder of, and to vote in respect of, the companys At 1 January 16.12 13.35 14.72 shares.
At 31 December 13.76 16.12 13.35 Decrease increase 14.6 % 20.7% 9.3 % Interests in voting rights High during the year 16.91 17.82 15.08 Other than as stated below, as far as we are aware, there are no Low during the year 13.24 13.35 13.18 persons with significant direct or indirect holdings in the company.
Information provided to the company pursuant to the Financial The table above sets out the middle market closing prices.
The Conduct Authoritys FCA Disclosure and Transparency Rules companys share price decreased by 14.6% in 2014.
This DTRs is published on a Regulatory Information Service and on compares with a decrease in the FTSE 100 index of 2.7% during the companys website.
The share price on 19 February 2015 was 15.26.
At 19 February 2015, the company had received notications in accordance with the FCAs DTRs of the following notiable UK US$ interests in the voting rights in the companys issued share capital: 18 75 Percentage of 17 70 No.
of issued 16 65 shares capital % 15 60 BlackRock, Inc. 304,779,454 6.27% 55 14 Legal & General Group Plc 149,809,659 3.08% 13 50 Percentage of Ordinary Shares in issue, excluding Treasury shares.
12 45 We have not acquired or disposed of any interests in our own 11 40 shares during the period under review, other than in connection 35 10 with our share buy-back programme.
09 30 31 12 11 31 12 12 31 12 13 31 12 14 UK share price UK US ADS price US$ 242 GSK Annual Report 2014 Strategic report Governance & remuneration Financial statements Investor information Nature of trading market The following tables set out, for the periods indicated, the high and low middle market closing quotations in pence for the shares on the London Stock Exchange, and the high and low closing prices in US dollars for the ADS on the NYSE.
Ordinary Shares representing the companys ADR programme, which is managed by the Depositary, are registered in the name of BNY Nominees Limited.
At 19 February 2015, BNY Nominees Limited held 863,571,705 Ordinary Shares representing 17.75% of the issued share capital excluding Treasury shares at that date.
At 19 February 2015, the number of holders of Ordinary Shares in the USA was 1,044 with holdings of 1,088,475 Ordinary Shares, and the number of registered holders of ADS was 26,022 with holdings of 431,785,852 ADS.
Certain of these Ordinary Shares and ADS were held by brokers or other nominees.
As a result, the number of holders of record or registered holders in the USA is not representative of the number of beneficial holders or of the residence of beneficial holders.
